Dr Maria-Victoria Mateos speaks to ecancer at ASCO 2024 about the results from the subgroup analysis for the phase 3 DREAMM-7 study.
This trial evaluated belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma.
In the previous analysis, BVd demonstrated a statistically significant and clinically meaningful progression-free survival benefit vs standard-of-care DVd.
Dr Mateos reports that there was improvement of 23 months in patients with RRMM and over 1 prior line of treatment.